Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gallbladder Diseases Clear all
Completed Phase 2 Interventional Results available

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

NCT03111732
View directory record Official record
Conditions
Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer, Gallbladder Cancer
Interventions
Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 25, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional

Randomized Trial of Percutaneous vs. Endoscopic Gallbladder Drainage

NCT07696546
View directory record Official record
Conditions
Acute Cholecystitis
Interventions
Percutaneous cholecystostomy, EUS-guided gallbladder drainage
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Natural Orifice Transgastric Endoscopic Surgical Removal of the Gallbladder

NCT01174069
View directory record Official record
Conditions
Cholecystitis
Interventions
NOTES assisted laparoscopic cholecystectomy
Procedure
Lead sponsor
The Oregon Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Phase 4 Interventional Results available

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

NCT02812186
View directory record Official record
Conditions
Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions
Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

NCT04164069
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
Interventions
Bevacizumab, Dasatinib, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Anne Noonan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 25, 2026, 5:26 AM EDT
Withdrawn Phase 4 Interventional

Outcome of IV Acetaminophen Use in Laparoscopic Cholecystectomies in Patients at Risk of OSA

NCT02056678
View directory record Official record
Conditions
Cholecystitis, Cholelithiasis, Obstructive Sleep Apnea
Interventions
acetaminophen, IV preparation
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 25, 2026, 5:26 AM EDT
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Recruiting Phase 3 Interventional

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

NCT07265674
View directory record Official record
Conditions
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Interventions
Nanvuranlat, Physician's Best Choice
Drug · Other
Lead sponsor
J-Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Duarte, California • Orange, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer

NCT00003276
View directory record Official record
Conditions
Gallbladder Cancer
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
20
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 25, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional

A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease

NCT06562179
View directory record Official record
Conditions
Hepatopancreaticobiliary and Foregut Operations
Interventions
da Vinci SP® Single-Port Robotic Surgical System
Device
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Active, not recruiting Phase 1 Interventional

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02495896
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions
Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Active, not recruiting Phase 3 Interventional

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Completed No phase listed Observational

Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder

NCT00489515
View directory record Official record
Conditions
Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

NCT01093222
View directory record Official record
Conditions
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Undifferentiated Gallbladder Carcinoma, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Interventions
Erlotinib Hydrochloride, Sorafenib Tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
141
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 25, 2026, 5:26 AM EDT
Active, not recruiting No phase listed Observational

Percutaneous Cholangiopancreatoscopy Registry

NCT05210322
View directory record Official record
Conditions
Biliary Stones, Cholangiocarcinoma, Intrahepatic, Biliary Stricture, Cholelithiasis, Choledocholithiasis
Interventions
Percutaneous cholangiopancreatoscopy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819
View directory record Official record
Conditions
Advanced Solid Tumors, HER2 Mutation
Interventions
BAY2927088
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Completed No phase listed Observational

Fetal Outcomes Among Pregnant Emergency General Surgery Patients

NCT05085353
View directory record Official record
Conditions
Pregnancy Complications, Acute Appendicitis, Acute Cholecystitis, Biliary Pancreatitis, Bowel Obstruction, Acute Diverticulitis
Interventions
non-obstetric acute general surgical disease
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

NCT04559139
View directory record Official record
Conditions
Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
Interventions
Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy, Partial Hepatectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
367
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

NCT00238212
View directory record Official record
Conditions
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Squamous Cell Carcinoma of the Gallbladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

NCT00789958
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions
capecitabine, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
251
States / cities
Anniston, Alabama • Little Rock, Arkansas • Berkeley, California + 181 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 25, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Emergency Ultrasound of the Gallbladder

NCT00388830
View directory record Official record
Conditions
Gallbladder Diseases
Interventions
Ultrasound
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 25, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional Results available

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

NCT01229111
View directory record Official record
Conditions
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Periampullary Adenocarcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
cediranib maleate, oxaliplatin, leucovorin calcium, fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Cleveland, Ohio • Columbus, Ohio • Mayfield Heights, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 25, 2026, 5:26 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Residual Bile Duct Stone by Peroral Cholangioscopy After Conventional ERCP

NCT03482375
View directory record Official record
Conditions
Gall Stones
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Manhasset, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 25, 2026, 5:26 AM EDT